24 related articles for article (PubMed ID: 1532343)
1. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Tanaka N; Sakamoto K; Okabe H; Fujioka A; Yamamura K; Nakagawa F; Nagase H; Yokogawa T; Oguchi K; Ishida K; Osada A; Kazuno H; Yamada Y; Matsuo K
Oncol Rep; 2014 Dec; 32(6):2319-26. PubMed ID: 25230742
[TBL] [Abstract][Full Text] [Related]
2. Chapter seven--Cancer treatment with gene therapy and radiation therapy.
Kaliberov SA; Buchsbaum DJ
Adv Cancer Res; 2012; 115():221-63. PubMed ID: 23021246
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for rectal cancer.
Krishnamurthi SS; Seo Y; Kinsella TJ
Clin Colon Rectal Surg; 2007 Aug; 20(3):167-81. PubMed ID: 20011198
[TBL] [Abstract][Full Text] [Related]
4. MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.
Flanagan SA; Krokosky CM; Mannava S; Nikiforov MA; Shewach DS
Mol Pharmacol; 2008 Sep; 74(3):863-71. PubMed ID: 18535288
[TBL] [Abstract][Full Text] [Related]
5. Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridine.
Perillo-Adamer F; Delaloye AB; Genton CS; Schaffland AO; Dupertuis YM; Buchegger F
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):613-20. PubMed ID: 16450135
[TBL] [Abstract][Full Text] [Related]
6. The application of 5-bromodeoxyuridine in the management of CNS tumors.
Freese A; O'Rourke D; Judy K; O'Connor MJ
J Neurooncol; 1994; 20(1):81-95. PubMed ID: 7807187
[TBL] [Abstract][Full Text] [Related]
7. Current status of radiation sensitization by fluoropyrimidines.
Pu AT; Robertson JM; Lawrence TS
Oncology (Williston Park); 1995 Aug; 9(8):707-14; discussion 714, 717-8, 721. PubMed ID: 7577371
[TBL] [Abstract][Full Text] [Related]
8. Dose-effect relationships and general mechanisms of combined exposures.
Streffer C; Müller WU
Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Jun; 51(6):961-9. PubMed ID: 3298107
[TBL] [Abstract][Full Text] [Related]
9. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization.
McGinn CJ; Miller EM; Lindstrom MJ; Kunugi KA; Johnston PG; Kinsella TJ
Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):851-9. PubMed ID: 7960987
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-induced modification of the effects of radiation and alterations in the cell cycle in normal and tumor mammalian cells.
Gorodetsky R; Levdansky L; Ringel I; Vexler A
Radiat Res; 1998 Sep; 150(3):283-91. PubMed ID: 9728657
[TBL] [Abstract][Full Text] [Related]
12. [Cytotoxicity of pentoxifylline and its effect on human hepatoma cell line Hep3b radiosensitivity].
Wu DH; Liu L; Chen LH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):305-7. PubMed ID: 16546733
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
Aschele C; Sobrero A; Faderan MA; Bertino JR
Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization.
Miller EM; Kinsella TJ
Cancer Res; 1992 Apr; 52(7):1687-94. PubMed ID: 1532343
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
